Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients
Conclusion:
Switching to B/F/TAF is well tolerated and effective in the real-world setting, even in patients with preexisting NRTI RAMs, such as M184V and RAMs conferring resistance to tenofovir. These results confirm the robustness of this combination.
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
More News: Clinical Trials | HIV AIDS | Infectious Diseases | Science | Study | Toxicology | Truvada | Viread | Virology | Women